NCT03706469View on ClinicalTrials.gov

A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK-831 Tablet Formulations in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 18, 2018

Primary Completion Date

December 11, 2018

Study Completion Date

December 22, 2018

Conditions
Healthy Volunteers
Interventions
DRUG

TAK-831 T2

TAK-831 T2 Tablets.

DRUG

TAK-831 T3

TAK-831 T3 Tablets.

Trial Locations (1)

68502

Celerion, Lincoln

Sponsors

Collaborators (1)

Takeda
All Listed Sponsors
collaborator

Takeda

INDUSTRY

lead

Neurocrine Biosciences

INDUSTRY